Clinical trials: Scleroderma
Systemic Sclerosis
Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel…
- Trial name
- NCT00707187
- Testing
- Cialis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Systemic Sclerosis
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in…
- Trial name
- NCT00704665
- Testing
- Relaxin
- Volunteers
- 231 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Autoimmune Diseases, Connective Tissue Diseases
Study of Silicone-Associated Connective Tissue Diseases
This study will examine the possible relationship between silicone implants or injections and the connective tissue diseases scleroderma and myositis.
- Conditions
- Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
- Trial name
- NCT00001330
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Sclerosis
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
This study compared the efficacy of different dosages of long-term iloprost treatment on Raynaud's phenomenon, ulcer healing, skin thickening, and progression of internal organ sclerosis in systemic sclerosis (SSc). Methods.
- Trial name
- ILODOSE (NCT00622687)
- Testing
- iloprost, iloprost low dose, iloprost therapy up to 2 ng/kg x min
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Achalasia, Nutcracker Esophagus
Comparison of Esophageal and Anorectal Manometry Catheters
The primary objective of this study is to compare the accuracy of esophageal and anorectal manometric pressure measurements using a newly developed air filled balloon catheter with present standard solid state esophageal and…
- Conditions
- Achalasia, Nutcracker Esophagus, Scleroderma, Esophageal Spasm
- Trial name
- NCT00204763
- Testing
- Air filled balloon catheter, Solid state catheter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Scleroderma, Systemic Sclerosis
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs.
- Trial name
- NCT00040651
- Testing
- Fludarabine, Cyclophosphamide, Thymoglobulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals
Systemic Scleroderma, Skin Fibrosis
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
Endothelin-1 is a potent vasoconstrictor and binds to two receptors, ET-A and ET-B, which are variable expressed on endothelial cells, smooth muscle cells, and fibroblasts.
- Conditions
- Systemic Scleroderma, Skin Fibrosis, Hand Functionality
- Trial name
- NCT00318175
- Testing
- Bosentan (Tracleer)
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Raynaud's Disease
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients…
- Trial name
- NCT00266669
- Testing
- Topical organogel with nitroglycerin
- Where
- 19 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Raynaud Disease, Raynaud Disease Secondary to Scleroderma
Lab Study of MQX-503 in Treatment of Raynaud's
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin…
- Conditions
- Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
- Trial name
- NCT00253331
- Testing
- topical organogel with nitroglycerin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Scleroderma, Systemic
Platelet Gel in Systemic Sclerosis
Systemic sclerosis (scleroderma; SSc) is a connective tissue disease characterized by a progressive fibrosis of the skin and visceral organs.
- Trial name
- NCT00463125
- Testing
- Platelet Gel
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Università Politecnica delle Marche
Systemic Sclerosis
Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis
The aim of this study was to assess serum N-terminal proBNP (NT-proBNP) in systemic sclerosis patients and to establish whether it reflects the severity of RV overload.
- Trial name
- NCT00453752
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Scleroderma, Diffuse
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Systemic sclerosis (scleroderma; SSc) is a rare, disfiguring systemic disorder characterized by fibrosis of the skin and visceral organs that alters every aspect of an individual life Although some features of scleroderma…
- Trial name
- NCT00428883
- Testing
- N-acetylcysteine (NAC)
- Where
- 5 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Università Politecnica delle Marche
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Systemic Sclerosis
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II.
- Trial name
- NCT00004380
- Testing
- relaxin
- Volunteers
- 1 people
- Sponsor
- National Center for Research Resources (NCRR)
Systemic Sclerosis, Raynaud Disease
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
- Trial name
- NCT00004786
- Testing
- iloprost
- Volunteers
- 200 people
- Sponsor
- National Center for Research Resources (NCRR)
Systemic Sclerosis
Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis
OBJECTIVES: I. Determine whether defects in fibrillin-1 cellular processing are present in the tsk1 mouse model that carries a known FBN1 gene rearrangement and in a population of Choctaw Native American patients with systemic…
- Trial name
- NCT00006393
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)